KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

CRISPR Therapeutics AG (CRSP) Revenue (2016 - 2025)

CRISPR Therapeutics AG's Revenue history spans 11 years, with the latest figure at $864000.0 for Q4 2025.

  • For Q4 2025, Revenue fell 97.58% year-over-year to $864000.0; the TTM value through Dec 2025 reached $3.5 million, down 90.59%, while the annual FY2025 figure was $3.5 million, 90.59% down from the prior year.
  • Revenue for Q4 2025 was $864000.0 at CRISPR Therapeutics AG, down from $889000.0 in the prior quarter.
  • Across five years, Revenue topped out at $900.7 million in Q2 2021 and bottomed at $6000.0 in Q4 2022.
  • The 5-year median for Revenue is $865000.0 (2025), against an average of $69.9 million.
  • The largest annual shift saw Revenue plummeted 99.98% in 2022 before it skyrocketed 3353333.33% in 2023.
  • A 5-year view of Revenue shows it stood at $12.9 million in 2021, then plummeted by 99.95% to $6000.0 in 2022, then surged by 3353333.33% to $201.2 million in 2023, then tumbled by 82.26% to $35.7 million in 2024, then tumbled by 97.58% to $864000.0 in 2025.
  • Per Business Quant, the three most recent readings for CRSP's Revenue are $864000.0 (Q4 2025), $889000.0 (Q3 2025), and $892000.0 (Q2 2025).